BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Medigen Biotechnology Corporation

Company Info

Name /Medigen Biotechnology Corporation

Address /14F, No. 3, Park St., Nangang District, Taipei 11503, Taiwan

Website /https://www.medigen.com.tw/en/home/

Presenter

Name /Ting-Wan Lin

Title /Executive Assistant to Chairman

Email /tingwan.lin@medigen.com.tw

Telephone /(Work) +886-2-7736-1234#860

Fax /

Mobile /

Company Type

Biotechnology

About the Company

Medigen is a biopharmaceutical company focusing on the development of new drugs and cell therapies for cancer treatments. Currently, two cell therapies are well established in Taiwan, Magicell®-NK and Magicell®- GDT. Both have shown enormous abilities to kill a wide spectrum of tumor cells with high cells number and purity. Currently, both cell therapies can be reached for cancer treatment in several hospitals under the Special Art. With the mission of guarding the life and health of human beings, Medigen will continue to make every possible endeavor to develop a full range of cell therapy services for needed populations.

Brief Description of main products or services

Magicell®-NK and Magicell®-GDT are two main cell products of Meigen. Magicell®-NK is a new generation of natural killer cell therapy by using Medigen’s state-of-the-art cell processing technology. Without adding any harmful material or feeder cells, high cell numbers of cells with high purity can be achieved. Most importantly, the cytotoxic activity of Magicell®-NK is also significantly high and shown strong evidence against a wide spectrum of tumor cells including liver, colon, kidney, and lung cancers. From current performance, no adverse effects were observed in multiple cell infusion. The product will be beneficial for both autologous and allogeneic applications for cancer treatment.

Magicell®-GDT is a gamma-delta T cell with well-established protective roles against cancers. Through our Japan partner, MEDINET, the product has shown remarkable clinical benefits in patients with various types of cancers at more than 50 medical institutions since 2007. Magicell®-GDT can also be combined with other therapies to improve the clinical responses. Currently, both Magicell®-NK and Magicell®-GDT are produced at Medigen’s cell processing center with GTP certificates and can be reached under the Special Act in Taiwan. Medigen is upholding the vision of “Innovations for a better life” and devoting ourselves to provide quality solutions for cancer patients continuously.

Contact Person

Name /Ting-Wan Lin

Email /tingwan.lin@medigen.com.tw

Phone /(Work) +886-2-7736-1234#860